Artelo Biosciences (ARTL) vs Matinas Biopharma (MTNB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Artelo Biosciences is the larger company by market cap ($1.3 million vs $890,711), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARTL | MTNB |
|---|---|---|
| Share price | $1.39 | $0.7999 |
| Market cap | $1.30M | $890.71K |
| 1-day change | -4.14% | -1.26% |
| EPS (TTM) | $-20.56 | $-17.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-12.88M | $-10.35M |
| 52-week high | $179.19 | $14.63 |
| 52-week low | $1.30 | $0.75 |
| Distance from 52-week high | -99.22% | -94.53% |
| Average volume | 476.69K | 80.86K |
| Shares outstanding | 937.18K | 1.11M |
| Employees | 7 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Artelo Biosciences
ARTL stock →Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Matinas Biopharma
MTNB stock →Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
ARTL vs MTNB FAQ
Which is bigger, Artelo Biosciences or Matinas Biopharma?
Artelo Biosciences (ARTL) is larger, with a market capitalization of $1.30M compared with $890.71K for Matinas Biopharma (MTNB).
Are Artelo Biosciences and Matinas Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.